Bad (Ab-155) Antibody
Description
The BAD Protein and Its Biological Significance
BAD (BCL2-associated agonist of cell death) is a pro-apoptotic member of the BCL-2 protein family that plays a crucial role in regulating programmed cell death. Known by several synonyms including BBC6, Bcl-2-binding component 6, Bcl-2-like protein 8, Bcl-xL/Bcl-2-associated death promoter, Bcl2 antagonist of cell death, and BCL2L8, this protein functions as a sentinel for cellular damage and stress signals .
The primary function of BAD is to promote apoptosis by binding to anti-apoptotic BCL-2 family proteins, neutralizing their protective effects and allowing the activation of pro-apoptotic proteins BAX and BAK. This interaction leads to mitochondrial outer membrane permeabilization, cytochrome c release, and ultimately, cell death through the intrinsic apoptotic pathway.
Antibody Production and Purification
The Anti-BAD (Ab-155) Antibody is produced through a carefully controlled immunization protocol. Rabbits are immunized with a synthetic peptide corresponding to amino acids 153-157 of mouse BAD, conjugated to keyhole limpet hemocyanin (KLH) to enhance immunogenicity . This region contains the critical serine-155 residue, which is a key regulatory phosphorylation site of the BAD protein.
Following immunization and antibody production, the antibody is purified using affinity chromatography with epitope-specific peptide . This purification method ensures high specificity by selecting only the antibodies that bind strongly to the target epitope, reducing background and cross-reactivity in experimental applications.
Validated Experimental Applications
The Anti-BAD (Ab-155) Antibody has been validated for several critical research applications, primarily Western Blot (WB) and Immunohistochemistry (IHC) . These applications enable researchers to detect and quantify BAD protein levels in various experimental contexts:
-
Western Blot (WB): This application allows for the detection and semi-quantitative analysis of BAD protein in cell and tissue lysates. The antibody can identify the specific band corresponding to the BAD protein, enabling researchers to monitor changes in protein expression under various experimental conditions or disease states.
-
Immunohistochemistry (IHC): This technique enables the visualization of BAD protein distribution within tissue sections, providing insights into its expression patterns in normal and pathological tissues.
Compatible Detection Systems
To visualize the binding of the primary Anti-BAD (Ab-155) Antibody, appropriate secondary antibodies are required. Several compatible secondary antibodies are available, including:
-
Goat Anti-Rabbit IgG H&L Antibody (AP)
-
Goat Anti-Rabbit IgG H&L Antibody (Biotin)
-
Goat Anti-Rabbit IgG H&L Antibody (FITC)
These secondary antibodies provide versatility in detection methods, allowing researchers to choose the most appropriate system for their specific experimental needs and equipment availability.
Regulation of BAD Function Through Phosphorylation
The functionality of BAD protein is tightly regulated through post-translational modifications, particularly phosphorylation. The protein contains several phosphorylation sites, with serine-155 being a critical regulatory residue . Phosphorylation of BAD at serine-155 significantly alters its binding properties and apoptotic function.
When BAD is phosphorylated at serine-155, its pro-apoptotic activity is inhibited . This phosphorylation disrupts the interaction between BAD and anti-apoptotic BCL-2 family proteins, preventing BAD from neutralizing their protective effects. Consequently, cells with phosphorylated BAD at serine-155 are less susceptible to apoptosis, promoting cell survival.
Signaling Pathways Controlling BAD Phosphorylation
Several kinase pathways regulate BAD phosphorylation at different serine residues, including serine-155. The phosphorylation state of BAD serves as an integration point for various cellular signals related to growth, metabolism, and stress. The Anti-BAD (Ab-155) Antibody provides researchers with a tool to investigate these regulatory mechanisms by detecting total BAD protein, allowing for comparative studies with phospho-specific antibodies.
| Phosphorylation Site | Effect on BAD Function | Relevant Kinases |
|---|---|---|
| Serine-155 | Inhibits pro-apoptotic activity | Protein Kinase A (PKA) |
| Serine-112 | Promotes 14-3-3 protein binding | MAPK, RSK |
| Serine-136 | Promotes 14-3-3 protein binding | Akt/PKB |
BAD-Mediated Apoptotic Pathway in Cancer Development
The BAD-mediated apoptotic pathway has been significantly associated with human cancer development and progression . Dysregulation of this pathway can contribute to the malignant transformation of normal cells by disrupting the balance between cell proliferation and apoptosis. Research indicates that the BAD-mediated apoptotic pathway influences cancer chemoresistance, suggesting its importance in therapeutic outcomes .
The Anti-BAD (Ab-155) Antibody provides researchers with a valuable tool to investigate BAD expression and its relationship to cancer development. By enabling the detection of total BAD protein, this antibody facilitates studies examining the role of BAD in various cancer types and stages, from pre-invasive to invasive cancers.
Potential Therapeutic Implications
Understanding the regulation of BAD through phosphorylation, particularly at the serine-155 site, has important implications for cancer therapy. Since phosphorylation at this site inhibits BAD's pro-apoptotic activity, therapeutic strategies that prevent this phosphorylation could potentially restore BAD's function and promote cancer cell death.
Research into the BAD-mediated apoptotic pathway using tools like the Anti-BAD (Ab-155) Antibody may lead to the development of novel targeted therapies that modulate BAD phosphorylation status to enhance cancer treatment efficacy. Additionally, the antibody can be used to monitor treatment responses by assessing changes in BAD expression or phosphorylation in patient samples.
Working Dilutions and Protocol Recommendations
For optimal results when using the Anti-BAD (Ab-155) Antibody, appropriate working dilutions should be determined empirically for each application and experimental system. The antibody's high concentration (1 mg/ml) allows for flexibility in dilution factors depending on the detection method and sample type .
For Western blot applications, it is advisable to start with dilutions in the range of 1:500 to 1:2000, while immunohistochemistry applications typically require dilutions between 1:100 and 1:500. Optimization of incubation times, blocking conditions, and detection systems will further enhance specificity and signal-to-noise ratio.
Controls and Validation Strategies
To ensure the reliability of results obtained with the Anti-BAD (Ab-155) Antibody, appropriate controls should be included in all experiments:
-
Positive Controls: Samples known to express BAD protein, such as specific cell lines with confirmed BAD expression.
-
Negative Controls: Samples with BAD knockdown or from BAD-knockout models.
-
Secondary Antibody Controls: Samples treated only with secondary antibody to assess background.
-
Peptide Competition Assays: Pre-incubation of the antibody with the immunizing peptide should abolish specific staining.
These controls help validate the specificity of the antibody and ensure that the observed signals accurately represent BAD protein expression.
Product Specs
Target Background
- This study demonstrates for the first time that genetic knockout of BAD provides protection against epileptic seizures in Kcna1-/- mice, a genetic model of epilepsy characterized by sudden unexplained death. PMID: 29171006
- BAD knockout significantly reduced epileptiform activity, an effect that was eliminated upon knockout or pharmacological inhibition of KATP channels. PMID: 29368690
- BAD is not essential for TNF-mediated cell death. PMID: 25611386
- Research suggests that regulation of BAD's pro-apoptotic activity plays a critical role in the pathological mechanisms leading to primary pigmented nodular adrenocortical disease tumor formation. PMID: 24865460
- Fasting may enhance beta-hydroxybutyrate uptake by reducing BAD levels in the brain during hypoglycemia. PMID: 25043191
- Findings indicate that insulin's downstream targets, including cyclin D1, BAD, alpha-MHC, and GATA-4, elucidate a molecular mechanism by which insulin promotes cell proliferation and differentiation. PMID: 24020834
- Our study suggests that BAD and Bmf jointly regulate lymphocyte homeostasis and limit spontaneous transformation through mechanisms that may not be exclusively linked to the induction of lymphocyte apoptosis. PMID: 22430207
- Results indicate that IKK inhibits TNFalpha-induced apoptosis through two distinct but cooperative mechanisms: activation of the survival factor NF-kappaB and inactivation of the proapoptotic BH3-only BAD protein. PMID: 23332762
- RNAi-mediated silencing of STAT1 in soft tissue sarcoma (STS) cells was sufficient to increase the expression of apoptotic mediators Fas and BAD, enhancing the sensitivity of STS cells to Fas-mediated apoptosis. PMID: 22805310
- BAD modulates counterregulatory responses to hypoglycemia and protective glucoprivic feeding. PMID: 22162752
- This study explored the regulation of BAD by uremic toxins and reported the sensitization of vascular smooth muscle cells to apoptosis upon BAD induction. PMID: 22172950
- Tonicity-induced COX-2 expression and PGE2 synthesis in the renal medulla involves phosphorylation and inactivation of the pro-apoptotic protein BAD, thereby counteracting apoptosis in renal medullary epithelial cells. PMID: 21716255
- Caspase-3 activation by the BAD-BAX cascade results in long-term depression induction in the hippocampus. PMID: 21609830
- JNK1 is necessary for erythropoietin-mediated cell survival through phosphorylation and inactivation of the pro-apoptotic, Bcl-2 homology domain 3 (BH3)-only Bcl-associated death protein (BAD). PMID: 21095239
- BAD protein collaborates with BIM protein in certain apoptotic responses and in suppressing g-irradiation-induced thymic lymphoma. PMID: 20431598
- Data reveals that loss of BMF reduced the pressure to inactivate p53, while BAD deficiency did not, identifying BMF as a novel component of the p53-independent tumor suppressor pathway triggered by c-Myc. PMID: 19965635
- Beta-arrestin 1-dependent ERK1/2 activation engaged by GLP-1 mediates the Ser-112 phosphorylation of BAD. PMID: 19915011
- The interaction of BAD with lipid rafts is a dynamic process regulated by IL-4 and plays a role in controlling apoptosis. PMID: 11907096
- Activation by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. PMID: 12011069
- Bcl-x(L) and Bcl-w target protein phosphatase 1alpha to BAD. PMID: 12115603
- Phosphorylation at serine 128 through activation of the JNK signaling pathway. PMID: 12189144
- BAD phosphorylation protects cells from the detrimental effects of apoptotic stimuli and attenuates death pathway signaling by increasing the threshold at which mitochondria release cytochrome c to induce cell death. PMID: 12431371
- BAD apoptotic protein, alone or in combination with BAX apoptotic protein and the prostatic-specific promoter ARR(2)PB, proved an effective therapy for experimental prostatic neoplasms. PMID: 12490000
- Candida albicans phospholipomannan promotes the survival of phagocytosed yeasts through modulation of BAD phosphorylation and macrophage apoptosis. PMID: 12551950
- HSV-1 US3 protein kinase blocks the caspases that cleave BAD at either residue 56 or 61, which is predicted to render the protein more proapoptotic, or at residue 156, which would inactivate the protein. PMID: 12743316
- Proapoptotic BAD suppresses tumorigenesis in the lymphocyte lineage. PMID: 12876200
- A combination of proteomics, genetics, and physiology indicates an unexpected role for BAD in integrating pathways of glucose metabolism and apoptosis. PMID: 12931191
- PP2A dephosphorylation of pSer112 is the key initiating event regulating BAD activation during interleukin-3 withdrawal-induced apoptosis. PMID: 12944463
- BAD is a substrate for PIM-2 oncogene proto-oncogene. PMID: 12954615
- Regulation of BAD phosphorylation actively mediates anti-IgM-induced apoptosis of immature B cells. PMID: 14585539
- JNK is essential for IL-3-mediated cell survival through phosphorylation and inactivation of the proapoptotic Bcl-2 family protein BAD. PMID: 14967141
- Data demonstrate that the Bcl-2 homology 3 domain-only protein, BAD, is involved in cell death following IL-7 withdrawal from D1 cells, an IL-7-dependent murine thymocyte cell line. PMID: 15123689
- Mechanisms that regulate the conversion of BAD from an anti-death to a pro-death factor include alternative splicing that produces N-terminally truncated BAD(S) and conversion by caspases into a pro-death fragment resembling the short splice variant. PMID: 15231831
- Alteration of lipid rafts is an early event in the apoptotic cascade indirectly induced by interleukin-4 deprivation via PP1alpha activation, dephosphorylation of cytoplasmic BAD, and caspase activation. PMID: 15634756
- BAD phosphorylation is not essential for PKB-mediated survival signaling in hemopoietic cells. PMID: 15843895
- Pak1-dependent Raf-1 phosphorylation regulates its mitochondrial localization, phosphorylation of BAD, and Bcl-2 association. PMID: 15849194
- BAD induces apoptosis upon detecting the coincidence of G2/M phase and growth factor deprivation. PMID: 15901741
- Phosphorylation of BAD Serine 128 exerts cell-specific effects on apoptosis. PMID: 15907327
- All three PIM kinase family members predominantly phosphorylate BAD on Ser112 and, additionally, are capable of phosphorylating BAD on multiple sites associated with the inhibition of the pro-apoptotic function of BAD in HEK-293 cells. PMID: 16403219
- Cellular cholesterol biosynthesis is critical for the activation and maintenance of the Akt-BAD cell survival cascade in response to growth factors such as insulin. PMID: 16513830
- These data establish a connection between calcium overload and mitochondria-mediated death pathways in outer hair cells and also suggest a dual role for BAD. PMID: 16521126
- The interaction of BAD with membranes is linked to binding of 14-3-3 protein and activation and membrane translocation of Bcl-XL. PMID: 16603546
- This study shows, using spectroscopic methods, that the BH3-only proteins BIM, BAD, and BMF are unstructured in the absence of binding partners. PMID: 16645638
- BAD was not required for cell death following IL-3 withdrawal, suggesting that changes to BAD phosphorylation play only a minor role in apoptosis. PMID: 16705087
- Both gonadotropin-releasing hormone and epidermal growth factor (EGF) caused rapid phosphorylation of BAD. PMID: 16741954
- The proapoptotic protein BAD is a key player in cell survival decisions, and is regulated post-translationally by several signaling networks. PMID: 17535812
- Raf-1 in beta-cells led to a significant loss of BAD phosphorylation at serine 112 and an increase in the protein levels of both BAD and BAX. PMID: 18006502
- These findings provide genetic evidence of the bifunctional activities of BAD in both beta cell survival and insulin secretion. PMID: 18223655
- Thr-201 phosphorylation of BAD by JNK1 is required for PFK-1 activation. PMID: 18469002
- BAD is the only BCL-2 family protein expressed in parietal cells. PMID: 18779780
Q&A
What is the Bad antibody and what are its applications in research?
The Bad antibody (such as #9292) is a primary antibody that detects endogenous levels of total Bad protein, which plays a critical role in apoptotic pathways. This antibody is specifically designed to recognize Bad protein without cross-reactivity with related proteins. Its applications include Western blotting (recommended dilution 1:1000) and immunoprecipitation (recommended dilution 1:100) . Bad protein has a molecular weight of approximately 23 kDa and the antibody demonstrates reactivity across multiple species including human, mouse, rat, and monkey samples, making it versatile for comparative studies .
What are anti-neurofascin antibodies and their relevance in neurological disorders?
Anti-neurofascin antibodies, particularly anti-NF155, are autoantibodies that target neurofascin proteins located at paranodal regions of myelinated axons. These antibodies are clinically significant biomarkers in a subset of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) . Research has identified different neurofascin isoforms as targets for autoantibodies, including NF155, NF186, and NF140, with some patients exhibiting reactivity to multiple isoforms . The antibodies are associated with distinctive clinical phenotypes, particularly treatment-resistant forms of CIDP characterized by sensory ataxia, and represent an important example of autoimmune nodopathy .
What are the general considerations for antibody validation in research applications?
Proper antibody validation requires multiple complementary approaches:
-
Specificity confirmation: Verify lack of cross-reactivity with related proteins
-
Detection sensitivity: Determine limits of detection for endogenous protein levels
-
Species reactivity: Confirm reactivity across relevant model organisms
-
Application suitability: Validate performance in specific applications (Western blot, immunoprecipitation, flow cytometry)
-
Control implementation: Use appropriate positive and negative controls
-
Reproducibility testing: Ensure consistent results across multiple experiments
-
Lot-to-lot consistency: Verify performance across different manufacturing lots
Researchers should document these validation steps thoroughly as part of experimental protocols to ensure reliable and reproducible results.
How do detection methods compare in identifying anti-NF155 antibodies?
Detection of anti-NF155 antibodies typically employs both cell-based assays (CBAs) and enzyme-linked immunosorbent assays (ELISAs), with complementary strengths:
| Detection Method | Advantages | Limitations | Best Practices |
|---|---|---|---|
| Cell-Based Assay (CBA) | Detects conformational epitopes; High specificity | Labor-intensive; Requires specialized equipment | Use human recombinant NF155-transfected HEK293 cells; Include non-transfected controls |
| ELISA | Quantitative; Higher throughput; Allows titer measurement | May miss conformational epitopes | Perform serial dilutions (1:100-1:40,000); Run samples in duplicate |
What is the clinical significance of IgG subclasses in anti-NF155 antibody detection?
The predominant IgG subclass in anti-NF155 antibodies has significant implications for pathophysiology and treatment response:
IgG4 is the predominant subclass in approximately two-thirds of patients with anti-NF155 antibodies . This subclass distribution is clinically significant because:
-
Pathogenic mechanism: IgG4 antibodies function primarily by blocking protein-protein interactions rather than activating complement or immune cells
-
Treatment implications: IgG4-predominant cases often show poor response to conventional treatments like intravenous immunoglobulin (IVIg) and corticosteroids
-
Alternative therapies: Rituximab (anti-CD20) shows good response in IgG4-predominant cases
-
Neuropathology: IgG4-mediated cases show distinctive pathology with Schwann cell terminal loop detachment without significant macrophage infiltration
Determining the IgG subclass using horseradish-peroxidase-conjugated mouse antihuman IgG1, IgG2, IgG3, and IgG4 secondary antibodies provides valuable information for predicting treatment response and understanding disease mechanisms .
What are the diagnostic performance characteristics of anti-NF155 antibody testing in CIDP?
Meta-analysis of anti-NF155 antibody testing reveals important diagnostic metrics for identifying the subset of CIDP patients with poor response to IVIg:
| Diagnostic Metric | Value | 95% Confidence Interval |
|---|---|---|
| Sensitivity | 0.45 | 0.29-0.63 |
| Specificity | 0.93 | 0.86-0.97 |
| Positive Likelihood Ratio | 6.5 | 3.3-13.1 |
| Negative Likelihood Ratio | 0.59 | 0.43-0.80 |
| Diagnostic Odds Ratio | 11 | 5-26 |
These metrics indicate that while anti-NF155 antibody testing has modest sensitivity (45%), it demonstrates excellent specificity (93%) . The positive likelihood ratio of 6.5 indicates that a positive test result is 6.5 times more likely in patients with IVIg-resistant CIDP than in those who respond well to IVIg. This makes anti-NF155 antibody testing particularly valuable as a rule-in test for identifying this specific CIDP subset .
What is the immunological profile of anti-NF155 antibody-positive CIDP compared to antibody-negative CIDP?
Anti-NF155 antibody-positive (NF155+) CIDP patients show a distinctive cytokine profile compared to antibody-negative (NF155-) patients:
-
Upregulated cytokines in NF155+ CIDP:
-
Significantly higher CXCL8/IL8 levels
-
Significantly higher IL13 levels
-
Elevated IL4 and IL10 levels
-
-
Downregulated cytokines in NF155+ CIDP:
-
Significantly lower IL1β levels
-
Significantly lower IL1ra levels
-
Reduced macrophage-related cytokines
-
-
Key discriminators between groups:
-
IL4, IL10, and IL13 are the three most significant discriminators
-
All three cytokines are required for IgG4 class switching
-
This distinctive cytokine profile explains the characteristic pathology with upregulation of both Th1 and Th2 cytokines and downregulation of macrophage-related cytokines, resulting in spinal root inflammation but lack of macrophage infiltration in sural nerves .
What are critical controls for flow cytometry experiments in antibody detection?
Flow cytometry experiments for antibody detection require rigorous controls to ensure accurate data interpretation:
-
Single-stain controls: Essential for proper compensation and must be run with every experiment, not just once per panel
-
Fluorescence Minus One (FMO) controls: Preferred over isotype controls for determining positive/negative boundaries
-
Isotype controls: Identify background staining but do not account for spreading error
-
Unstained controls: Establish baseline autofluorescence
-
Biological controls: Include known positive and negative samples when possible
The absence of proper controls, particularly single-stain controls, is a significant red flag in flow cytometry experiments. Without these controls, compensation matrices cannot be properly adjusted for day-to-day variations in antibody staining, fluorophore stability, and instrument performance .
Why is proper sample labeling critical in antibody detection experiments?
Proper labeling of parameters and tubes in antibody detection experiments is essential for accurate data interpretation and reproducibility:
-
Parameter labeling: All fluorescence channels should be clearly labeled with both fluorophore and target molecule (e.g., "FITC-CD3" rather than just "FITC")
-
Tube labeling: Sample identifiers should include treatment conditions, genotypes, and other relevant experimental variables
-
Standardized nomenclature: Following guidelines such as MIFlowCyt and the Probe Tag Dictionary ensures consistency across experiments and laboratories
-
Data traceability: Comprehensive labeling creates an audit trail connecting raw data to experimental conditions
What are the considerations for using compensation beads versus cells in antibody detection?
The choice between compensation beads and cells for single-stain controls involves important technical considerations:
| Aspect | Compensation Beads | Single-Stained Cells |
|---|---|---|
| Advantages | Require fewer cells; Consistent signal; Work well for low-abundance markers | More accurately reflect true fluorophore behavior in experimental samples |
| Limitations | May show different emission spectra for some fluorophores; Potential matrix mismatch | Require sufficient cell numbers; May be difficult with rare populations |
| Fluorophore compatibility | Problems more common with polymer dyes (BUV, BV, BB, Super Bright) | Generally reliable across fluorophore types |
| Bead selection | UltraComp/UltraComp Plus superior to AbC beads for polymer dyes | Not applicable |
While compensation beads are convenient, the fluorophore emission spectra can differ between beads and cells for reasons not fully understood. This phenomenon can lead to suboptimal compensation when bead-derived matrices are applied to cellular samples. When using beads, researchers should verify compensation accuracy by examining potential spillover in final cellular samples .
What approaches are used to evaluate changes in antibody titers during disease progression?
Monitoring changes in antibody titers during disease progression requires systematic approaches:
-
Serial sampling: Collect serum at defined intervals during disease course
-
Standardized dilution series: Perform consistent dilutions (typically 1:100 to 1:40,000) across timepoints
-
Duplicate testing: Run all samples in duplicate to control for technical variability
-
Optical density (OD) measurement: Track changes in ELISA OD values as a quantitative measure of antibody levels
-
Subclass monitoring: Assess potential changes in IgG subclass distribution over time
-
F(ab')2 fragment analysis: Generate and test F(ab')2 fragments to evaluate potential neutralization of antigen-specific binding sites
-
Clinical correlation: Associate antibody titer changes with clinical metrics of disease activity
These approaches were utilized in studies of anti-NF155 antibodies to track antibody levels during disease progression and treatment response . For example, one study performed additional tests on a patient with anti-NF155 seropositivity who had undergone serial serum sampling to evaluate changes in OD values during the course of disease .
How does treatment response differ in anti-NF155 antibody-positive versus antibody-negative CIDP patients?
Treatment response in anti-NF155 antibody-positive CIDP patients shows distinctive patterns:
| Treatment | Response in NF155+ Patients | Recommendations |
|---|---|---|
| Corticosteroids | Partial or no response in most patients (5/6 in one study) | Not first-line therapy |
| Intravenous Immunoglobulin (IVIg) | Partial or poor response in most patients (5/6 in one study) | Not first-line therapy |
| Rituximab | Good response in most patients (3/3 in one study) | Consider as early treatment |
This distinctive treatment response pattern underscores the importance of early anti-NF155 antibody testing, especially in young CIDP patients presenting with sensory ataxia. Early identification allows for appropriate treatment selection, potentially avoiding delays in effective therapy .
What is the long-term prognosis for patients with anti-NF155 antibody-positive CIDP?
The long-term outcomes for anti-NF155 antibody-positive CIDP patients remain incompletely characterized, but available data suggests:
These prognosis statistics must be interpreted cautiously due to small sample sizes and heterogeneous follow-up periods across studies. The evidence suggests that anti-NF155 antibody-positive CIDP may have a worse prognosis than antibody-negative CIDP, particularly if optimal treatment is delayed .
What methodological approaches are recommended for antibody subclass determination?
Determining antibody subclasses requires specific methodological considerations:
-
Detection antibodies: Use horseradish-peroxidase-conjugated mouse antihuman IgG1, IgG2, IgG3, and IgG4 secondary antibodies at appropriate dilutions (typically 1:5,000)
-
Standardized serum dilution: Maintain consistent dilution (typically 1:100) across subclass testing
-
Control samples: Include known IgG subclass-positive controls and healthy controls
-
Quantitative analysis: Measure optical density values to determine relative abundance of each subclass
-
Predominance determination: Define predominance based on significantly higher levels of one subclass compared to others
This approach has successfully identified IgG4 as the predominant subclass in approximately two-thirds of anti-NF155 antibody-positive CIDP patients, which correlates with distinctive clinical phenotypes and treatment responses .
What genetic factors influence development of autoimmune responses to neurofascin?
Genetic factors, particularly HLA haplotypes, play a significant role in susceptibility to developing autoantibodies against neurofascin:
-
HLA associations: All Japanese patients with NF155+ CIDP have one of two specific human leukocyte antigen (HLA) haplotypes
-
Key haplotypes: HLA-DRB115:01-DQB106:02 shows significantly higher prevalence in patients with anti-NF155 antibodies
-
Geographic variations: Genetic associations may vary across different populations
-
Implications: Suggests genetic predisposition contributes to breaking immune tolerance to neurofascin
-
Research applications: HLA typing may help identify patients at risk for developing anti-NF155 antibodies
These genetic associations provide insight into the immunopathogenesis of anti-NF155 antibody-positive CIDP and may guide future research into preventive strategies or personalized treatment approaches .
